FDA 修订药品再包装与再贴标企业合规项目 7356.002B 并更新实施日期
Drug Repackagers and Relabelers (7356.002B)
FDA 更新药品再包装与再贴标企业检查合规项目 7356.002B,实施日期为 2015 年 9 月 11 日,修订内容涉及实施日期、完成日期、组织与程序变更及项目联系人。该项目依据 21 CFR 210 和 211 指导对再包装与再贴标企业的 CGMP 检查,并给出简略检查与全面检查两种选项。项目不覆盖无菌产品、放射性药品的再包装再贴标及医用压缩气体的再贴标,进口产品也不在本项目范围内。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
PROGRAM 7356.002B
CHAPTER 56 - DRUG QUALITY ASSURANCE
SUBJECT: IMPLEMENTATION DATE
DRUG REPACKAGERS AND RELABELERS
09/11/2015
Revision Note: Program revised 09/11/2015 to
update implementation date, completion date, COMPLETION DATE
organizational/procedural changes and program
contacts.
DATA REPORTING
PRODUCT CODES PRODUCT/ASSIGNMENT CODES
Industry Codes: 50, 54-56, 56002B
and 60-66 inclusive.
FIELD REPORTING REQUIREMENTS
Establishment Inspection Reports (EIRs) are to be created and filed
electronically using the drug repackers/relabelers specific module in
TurboEIR or replacement system that is accessible to both ORA and CDER.
For inspections of routine commercial manufacturing classified as Official
Action Indicated (OAI) due to failure to comply with 21 CFR Part 210 and 211
Current Good Manufacturing Practice (CGMP) as they apply to drug
repackagers/relabelers, submit advisory, administrative, or judicial action
recommendations via MARCS-CMS in accordance with the Regulatory Procedures
Manual (RPM).
Districts should immediately report significant issues according to current
FACTS, Panorama and CMS procedures. This includes promptly filing and
changing OAI notifications.
During an inspection, if you obtain information pertaining to inadequate
adverse drug experience (ADE) reporting, unapproved drug issues, or post-
approval reporting violations (application supplements, Field Alert Reports
(FARs), etc.), report in accordance with directions provided in the
applicable compliance programs and under separate captions in the EIR. Data
system information about these inspectional activities should be reported
under separate Program Assignment Codes (PACs). Expansion of coverage under
these programs into a CGMP inspection should be reported under this
compliance program.
TRANMITTAL NO 02-01 (12/27/93) PART IPAGE 1 of 2
FORM FDA 2438g (10/91)
第 2 页
PROGRAM 7356.002B
The Districts are requested to use this compliance program for all drug
repackager/relabeler inspections.
TRANMITTAL NO 02-01 (12/27/93) PART IPAGE 2 of 2
FORM FDA 2438g (10/91)
第 3 页
PROGRAM 7356.002B
PART I - BACKGROUND
The repackaging and relabeling of drugs under Current Good Manufacturing
Practice (CGMP) controls has been a problem of long standing. Product
mix-up, loss of product identity, contamination and cross-contamination,
lack of stability data to support expiration dates and the lack of
adequate control systems have been frequently documented.
Drug repackaging and relabeling are manufacturing processes which must be
conducted in accordance with applicable CGMP requirements. The
repackager/relabeler is performing the operations a formulator would
handle if the formulator was packaging the product into consumer-sized
containers.
TRANMITTAL NO 02-01 (12/27/93) PART I PAGE 1 of 1
FORM FDA 2438g (10/91)
第 4 页
PROGRAM 7356.002B
PART II - IMPLEMENTATION
OBJECTIVES
To provide uniform guidance and a means of assessing the operations of drug
repackagers and relabelers as they relate to the provisions of the Current
Good Manufacturing Practice (CGMP) Regulations, 21 CFR 210 and 211.
To initiate regulatory follow up for operations which deviate from CGMP’s?
To identify whether there is a need for specific CGMP's for the regulation
of these operations.
To assess the compliance with all labeling requirements of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) and its implementing regulations for
repackaged drugs.
PROGRAM MANAGEMENT INSTRUCTIONS
The program includes, but is not limited to, the following operations:
− repackaging of solid and liquid bulk-dosage forms into smaller
packages (may include larger containers such as pints, quarts, half
gallons, 1000 tablet bottles, etc.) ;
− repackaging from conveyances (e.g., tank cars) into smaller containers
such as drums;
− contract packagers who package expressly for manufacturers of dosage
forms;
− repackagers or relabelers of antibiotics; and
− shared services operations (shared services operations servicing HMO's
and hospital groups may be extensive operations.)
Exclusions:
− repackagers/relabelers of sterile products, radioactive drugs, and
relabelers of compressed medical gases.
− Pre-packagers operating within the practice of pharmacy and
distributing (selling) drugs upon receipt of written prescriptions.
TRANMITTAL NO 02-01 (12/27/93) PART II PAGE 1 of 3
FORM FDA 2438g (10/91)
第 5 页
PROGRAM 7356.002B
DEFINITIONS
Unit of Use: A method of packaging *drug product* into a
single container which contains more than one
dosage unit, usually sufficient quantity of
medication for one normal course of therapy.
Unit Dose: *A method of packaging a drug product into a non
re-usable container designed to hold a quantity
of drug intended for administration as a single
dose directly from that container.*
*For the purpose of differentiating whether an establishment is acting as a
pharmacy or as a repackager/relabeler, the repackaging of drug products by
licensed pharmacists, i.e. filling prescriptions for identified patients is
within the regular practice of pharmacy. The repackaging of drug products by
pharmacists, or any other entity, for resale or distribution to hospitals,
other pharmacies, nursing homes, health care facilities, etc., are beyond
the practice of pharmacy and these repackaging/relabeling facilities are
thus required to register and list all such drug products with FDA.*
STRATEGY
The program strategy requires the review of a firm's quality assurance
system(s) against CGMP requirements to determine their adequacy, and
auditing these systems (including SOPs) during inspections. CGMP
inspectional coverage shall be sufficiently complete to assess the adequacy
of all significant drug repackaging/relabeling process and control systems.
The frequency and depth of inspection should be determined by the firm's
history, and/or the technology employed or the kind of product. When a
process is inspected for a particular product, the inspection of that
process may be considered applicable to all products which use it. The
program also requires a review of the labeling of the repackaged drugs to
determine if they are in compliance with the Act.
The District is responsible for the depth of coverage given to each drug
process. The Districts are expected to prioritize and schedule more frequent
inspections, as appropriate, taking into consideration the firm's
compliance history, along with product characteristics.
Consider using inspection teams which include a chemist or microbiologist,
particularly to assess a firm's laboratory controls.
TRANMITTAL NO 02-01 (12/27/93) PART II PAGE 2 of 3
FORM FDA 2438g (10/91)
第 6 页
PROGRAM 7356.002B
ORA, OMPTO, DIVISION OF Medical Products and Tobacco Program Operations
Resolve difficulties in inspectional reporting.
Identify headquarters or field personnel (if other than Home District) who can
provide special expertise and arrange for their assistance I the performance of
inspections, as necessary.
TRANMITTAL NO 02-01 (12/27/93) PART II PAGE 3 of 3
FORM FDA 2438g (10/91)
第 7 页
PROGRAM 7356.002B
PART III - INSPECTIONAL
OPERATIONS
Inspections will be conducted in accordance with CP 7356.002 Drug Process
Inspections as far as applicable. These will include Unit Dose
repackagers and Shared Services operations.
Inspectional Options
This program circular provides two inspectional options: Abbreviated
Inspectional Option, and Full Inspectional Option *(For this program, the
Full Inspectional Option provides specific policies for Unit-Dose
Repackagers.)* To determine which option should be used, an evaluation of
the following is appropriate.
1. Review and Evaluation
a. Determine if changes have occurred by comparing current operations
against the EIR for the previous full inspection. The following
type of changes are typical of those that would warrant the full
inspectional option:
1. New potential for cross-contamination (see Part III, page 5,
item 8) or mix-ups arising through changes in process or
product line.
2. Use of new technology requiring new expertise, significantly
new equipment, or new facilities.
3. A change in the personnel directly involved in the
repackaging/relabeling operation.
b. Review the firm's complaint file, Drug Quality Reporting System
(DQRS), etc., and determine if the pattern of complaints (or
other information available to the District) as well as the
firm's records of internal rejection warrant expanding the
inspection to the full inspectional option to look for weaknesses
in the firm's processes, systems or controls.
Review the firm's ANDA and AADA applications and confirm that
requirements are being followed.
C. If no significant changes have occurred and no violative
conditions are observed, the abbreviated inspectional option may
be adequate.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 1 of 9
FORM FDA 2438g (10/91)
第 8 页
PROGRAM 7356.002B
d. If significant changes have occurred, or if violative or
potentially violative conditions are noted, the inspection
should be expanded to the full inspectional option to provide
appropriate coverage.
e. If an inspection needs to be expanded to the full inspe6tional
option, it need be expanded only for the general product or
process area in question.
f. Review the firm's labeling for misbranding violations *and
determine if the nature and extent of violations warrant
expanding the inspection to the full inspection option in
order to look for deficiencies in the firm's labeling processes,
systems, or controls.*
2. Abbreviated Inspectional Option
This option involves a brief inspection of the repackager/relabeler
to maintain surveillance over the firm's activities. An abbreviated
inspection as described below is adequate for routine coverage and
will satisfy the biennial inspection requirement. The use of this
option is designed to save inspectional and clerical resources.
*This option should not be used on an initial inspection of a
facility, nor when the District's review of information such as,
past history, results of sample analysis, complaints, DQRSs, recalls,
etc., indicates that an abbreviated inspectional option is not
appropriate for a specific firm.*
a. Perform an inspection of the firm's repackaging/relabeling
facility including master records and batch records for a
representative number of products repackaged/ relabeled by the
firm. Products with a history of previous labeling problems
should be included. *Special note should be taken of the
firm's repackaging and relabeling controls.*
For products required to be packaged in tamper-resistant (TRP)
packaging, determine the adequacy of the firm's TRP and
required labeling statement (see Part VI, References, Page 1,
Items F, G, and H).
Any observations of inadequate controls or other significant
objectionable conditions will indicate that a full inspection
should be performed.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 2 of 9
FORM FDA 2438g (10/91)
第 9 页
PROGRAM 7356.002B
b. The minimum reporting required for an abbreviated inspection
is described in IOM 593.1. Include a brief summary describing the
scope of the inspection, the persons interviewed and any changes
which may have occurred since the previous inspection.
3. Full Inspectional Option
This option may involve a complete inspection of all
systems and processes or a particular product or process
as noted in 1.d. and e. above. A full inspection may also
be conducted on a surveillance basis at the District's
discretion. It is not anticipated that full inspections
will necessarily be conducted every 2 years. They may be
conducted at less frequent intervals, perhaps every third
or fourth inspection. Also, whenever information becomes
known which would question the firm's ability to produce
quality products, an appropriate in-depth inspection
should be performed.
a. All Repackaging/Relabeling operations
The following applicable portions of the CGMP's must
be considered during inspections of
repackaging/relabeling operations:
1) Buildings
Evaluate the building facilities employing the
standards enumerated in 21 CFR 211.42, 211.44,
211.46, 211.48, 211.50, 211.52, 211.56, and
211.58.
2) Equipment
Evaluate the equipment, equipment cleaning, and
maintenance procedures employing the standards
stated in 21 CFR 211.63, 211.65, 211.67, and
211.68.
3) Personnel (21 CFR 211.22, 211.25, 211.28, 211.34)
a) Determine the qualifications, background,
training and number of personnel engaged in
the repackaging/relabeling operations.
b) Where there is a formalized instruction and
training program for personnel, determine
whether it is an initial or on-going
operation.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 3 of 9
FORM FDA 2438g (10/91)
第 10 页
PROGRAM 7356.002B
c) Determine whether there are formalized
procedures to fulfill the requirement of 21
CFR 211.22(d).
4) Drugs For Repackaging or Relabeling
a) The firm should carefully examine all
incoming drug products for repackaging and
relabeling to ascertain that the bulk
containers of finished dosage form drug
products are received intact, undamaged, and
completely and properly labeled as received.
b) Evaluate the procedures employed by the firm
in the receipt, handling, and storage of drug
products for repackaging or relabeling.
c) *Drugs having a high volatility, such as
nitroglycerin sublingual tablets, should not
be repackaged. See Compliance Policy Guide
7132b.11 -- Expiration Dating of Unit Dose
Repackaged Drugs.*
5) Control Records
Evaluate the control record-keeping system used by the
firm for their repackaging/relabeling operations. Use
the standards contained in 21 CFR 211.180; 211.182;
211.184; 211.186(a), (b)(1), (2), (8), (9);
211.188(a), (b)(1-13); 211.192; 211.198.
6) Production and Control Procedures
*Only one drug product is to be brought into a
repackaging area at a time. Upon completion of the
repackaging operation, all remaining unused stock and
finished stock are to be removed from the area. The
packaging machinery is to be completely emptied,
cleaned, and inspected before setting the equipment up
for the repackaging of another drug product.*
a) The following sections of 21 CFR 211 apply in
evaluating a repackager/relabeler's adherence
to CGMP requirements: 211.100, 211.103,
211.105, 211.110, 211.111, 211.113, 211.122,
and 211.130.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 4 of 9
FORM FDA 2438g (10/91)
第 11 页
PROGRAM 7356.002B
b) Where applicable, the term "production" or
"manufacturer" includes "repackaging" and
"relabeling" operations as contained in 21
CFR
211.100, 211.103, 211.105.
7) Product Containers and their Components
Review the firm's specifications and SOPs regarding
selection and handling of containers and closure systems
(21 CFR 211.84). Evaluate the suitability of containers
and closure systems with regard to 21 CFR
211.94. Report and document deficiencies.
8) Packaging and Labeling
Evaluate the firm's adherence to the following CGMP
requirements for packaging and labeling operations. The
following criteria of 21 CFR 211 are applicable for the
purposes of this program: 211.122, 211.125, 211.130,
211.132, and 211.134.
For products required to be packaged in
tamper-resistant (TRP) packaging, determine the
adequacy of the firm's TRP and required labeling
statement (see Part VI, References, Page 1, Items F, G,
and H).
The manufacture of penicillin must be separate from
other drug products, including cephalosporin. The
specific requirements for such separation are covered
in Sections 211.42(d) and 211.46(d) of the current Good
Manufacturing Practice regulations.
There is no specific prohibition against the
manufacture or repackaging, of cephalosporin drug
products in the same facility as other non-penicillin
drug products. However, FDA discourages such practice
since there is some clinical and laboratory evidence of
partial cross-allergenicity of the penicillins and
cephalosporins and the subsequent possibility that a
patient could be hypersensitive to a cephalosporin
received from a contaminated non-penicillin drug
product.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 5 of 9
FORM FDA 2438g (10/91)
第 12 页
PROGRAM 7356.002B
At the present time, there is no formal guidance on
the separation of cephalosporin from the non-
penicillin products beyond the present provisions in
the CGMP regulations relating to control of cross-
contamination between non-penicillin drug products.
However, regulations do require appropriate controls
to prevent cross-contamination.
9) Stability
Evaluate the stability testing program. Determine whether
stability studies are conducted by the firm, or for the
firm, and whether such documentation is, in fact, a part
of the record-keeping system maintained by the
repackager/relabeler. For program purposes, evaluate on
the basis of 21 CFR 211.166(a), (b), (c).
Determine if the firm uses expiration dating periods
beyond those used by the manufacturer and, if so, the
rationale. Carefully evaluate the basis for any
extensions. They must be based on adequate stability data
and necessary awareness of any changes in the formula or
manufacturing procedures used by the manufacturer.
10) Laboratory Controls
Determine whether the firm has an established and on-going
control program. It is not necessary to perform chemical
analyses on oral solid drug products in finished dosage
form, provided adequate physical identification of the
drug to be repackaged is performed *(See Compliance Policy
Guide 7132.13).* Determine whether accurate and
meaningful test results or examinations are performed by
the repackager, such as, organoleptic examinations of
incoming bulk drug products, visual inspection of
labeling, and, where appropriate, stability data to
justify assigned expiration dates. The following 21 CFR
211 criteria are applicable: 211.194; 211.160(a), (b)(1,
3 & 4); 211.170(a), (b) and 211.176.
(For purposes of this program the term "manufacturing"
includes "repackaging operations.")
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 6 of 9
FORM FDA 2438g (10/91)
第 13 页
PROGRAM 7356.002B
11) Distribution Records
Evaluate the firm's distribution records systems and
determine whether the criteria of 21 CFR 211.142 and
211.150 are met.
12) Expiration Dating
Evaluate the expiration dating system as it pertains to
stability information under 21 CFR 211.137. Pertinent program
criteria are listed in 21 CFR 211.137(a), (b), (c).
The expiration date on the manufacturer's original
container may be assigned to a solid oral dosage form
repackaged *into a "unit-of-use” or other container
/closure system containing more than a single dose,* which
is equal to or better than the original container /closure
system provided all labeling statements pertaining to
storage conditions as specified by the original
manufacturer are also used in and on the new labeling. This
expiration policy does not apply to liquids, creams,
ointments and suspensions.
13) Complaint Files
Criteria are listed in 21 CFR 211.198. Evaluate the firm's
system and policy regarding product complaints other than
those of an economic nature. Determine whether meaningful
investigations are made and proper dispositions are handled
in accordance with 21 CFR 211.192.
*b. Unit Dose Repackagers
For this program the full inspectional option provides specific
policies for Unit-Dose Repackagers.
The following practices, if completely met, are adequate to
allow Unit Dose repackagers to comply with current good
manufacturing practices in the specific areas described below.
For all other areas, follow guidance in 3a:
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 7 of 9
FORM FDA 2438g (10/91)
第 14 页
PROGRAM 7356.002B
1) Expiration Dating for Unit Dose Containers:
A unit dose container is a non-reusable container designed
to hold a quantity of drug intended for administration as a
single dose, which is to be used promptly after the
container is opened.
A firm may repackage solid oral dosage forms into unit dose
containers and utilize an expiration date of not more than
six months from the date of repackaging without conducting
stability studies, provided that all of the following
conditions are met:
a) The unit dose container complies with the Class A or
Class B standard described in the current revision of
the United States Pharmacopeia, Physical Tests,
Single-Unit Containers and Unit-Dose Containers for
Capsules and Tablets.*
*b) The original bulk container has not been previously
opened and the entire contents are repackaged in one
operation.
c) The expiration period does not exceed 25 percent of
the remaining time between the date of repackaging
and the expiration date shown on the original
manufacturer's bulk, container of the drug
repackaged.
d) The repackaging and storage of the drug product is
accomplished in a humidity controlled environment and
within the temperature specified in the USP monograph
or the product labeling. If no temperature/humidity is
specified, a controlled room temperature, as defined
by the USP, with a relative humidity not exceeding 75
percent should be maintained. *Documentation must be
on file to verify that all the conditions listed above
are met.*
2) Labeling:
In addition to the general packing and labeling
requirements (see Part III, Page 5, Item 8), all unit dose
repackaged products are to be placed into larger containers
and each container must be fully labeled prior to removal
from the premises.*
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 8 of 9
FORM FDA 2438g (10/91)
第 15 页
PROGRAM 7356.002B
LABELING REQUIREMENTS
See Attachment A - Labeling Requirements for Solid Oral Dosage Forms
in Unit Dose Containers
See Attachment B - Inspectional Guidance on Label Controls
All the repackaged drugs must be labeled to meet the requirements of
the Act and its implementing regulations. *The labeling requirements
in Attachment A are for guidance and any deficiencies in labeling
should be documented and reviewed by the district compliance office
to determine, if a recommendation for regulatory action, to the
Office of Compliance, Office of Unapproved Drugs and Labeling
Compliance (OUDLC) is warranted.*
SAMPLE COLLECTION
Collect samples to fully document serious deviations from CGMP and
the likelihood of product quality problems as well as any labeling
violations. Physical samples must be collected in the case of
suspected identity, potency, decomposition, contamination and/or
labeling problems. The following are areas of concern when deciding
whether a physical sample is warranted:
A. Lack of assurance that the incoming drugs are what they
purport to be;
B. Lack of assurance that no mix-up occurs between drugs
during the repackaging/relabeling operations; and
C. Lack of assurance that the finished product is properly
labeled.
IMPORTS
No coverage under this program.
TRANMITTAL NO 02-01 (12/27/93) PART III PAGE 9 of 9
FORM FDA 2438g (10/91)
第 16 页
PROGRAM 7356.002B
PART IV - ANALYTICAL
See Compliance Program, Drug Process Inspections (7356.002).
TRANMITTAL NO 02-01 (112/27/93) PART IV PAGE 1 of 1
FORM FDA 2438g (7/97)
第 17 页
PROGRAM 7356.002B
PART V - REGULATORY/ADMINISTRATIVE STRATEGY
When non-compliant conditions are identified, voluntary,
administrative and/or regulatory options currently available should
be initiated (See RPM Part 8). Regulatory recommendations should be
based on well-documented and significant CGMP deviations and/or
labeling violations.
The following examples may be considered significant deviations if
they are not isolated instances, and could reasonably be expected to
have an impact on product quality: .
1. Lack of valid stability data for the container/closure system
used. Stability data may be accepted by the
repackager/relabeler from a suitable source, provided the data
can assure the stability of the product in the
container/closure system used. This data must be readily
available at the repackager/relabeler facility.
2. Lack of control procedures and/or records sufficient to support
the integrity of the product, and to identify lots or batches
of drug products repackaged or relabeled.
3. Lack of control procedures and/or records to provide assurance
that labeling mix-ups will not occur.
The above referenced significant deviations do not represent the
only criteria which could adversely impact product quality. In
varying factual situations, some of the above may become less
significant while conditions not mentioned may become serious
failures. All deviations have to be evaluated as to whether there is
assurance that the incoming drug is what it purports to be, that
there is no product mix-up and that the finished product is properly
labeled.
Refer to Part V of the Drug Process Inspection Program for general
information on Regulatory Procedure.
If GMP deviations are noted with regard to packaging and label
controls, districts should consider issuance of a *warning letter.*
If significant deviations are found, the Center will consider
additional regulatory action, especially if the firm has had multiple
label recalls.
If label/labeling violations are suspected following a label/labeling
evaluation based on CPG 7132b.10 and Attachment A, OC/OUDLC should be
contacted to determine what course of action to follow. *Before the
district concludes an inspection of any
TRANMITTAL NO 02-01 (12/27/93) PART V PAGE 1 of 2
FORM FDA 2438g (10/91)
第 18 页
PROGRAM 7356.002B
pharmacy supplying repackaged drugs in limited quantities to a health
care facility to supplement existing prescriptions from that
pharmacy, contact OC/OUDLC(301) 796-3100 for a discussion of the
extent of the operation.*
The issuance of *warning letters* which include label/labeling
violations must be discussed with OC/OUDLC before issuance. This
Compliance Program does not authorize the use of *warning letters*
for drug misbranding violations.
TRANMITTAL NO 02-01 (12/27/93) PART V PAGE 2 of 2
FORM FDA 2438g (10/91)
第 19 页
PROGRAM 7356.002B
PART VI - REFERENCES, ATTACHMENTS AND PROGRAM CONTACTS
REFERENCES
A. Inspection Operations Manual, Sub-chapter 540
B. 21 CFR, Part 210, 211
C. Compliance Policy Guide, 7132.13, "Repacking of Drug
Products - Testing/Examination under CGMPs11
D. Compliance Policy Guide, 7132b.10, "Unit Dose Labeling for
Solid and Liquid Oral Dosage Forms"
E. Compliance Policy Guide, 7132b.11, "Expiration Dating of
Unit Dose Repackaged Drugs"
F. Regulatory Procedures Manual, Chapter 8
G. Compliance Policy Guide, 7132a.17, "Tamper-Resistant
Packaging Requirements for Certain Over-the-Counter (OTC)
Human Drug Products"
H. Federal Register, Vol. 54, No. 21, pp. 5227-5229, February
2, 1989, Final rule, Tamper-Resistant Packaging
Requirements for Certain Over-the-Counter (OTC) Human
Drug Products
I. Compliance Policy Guide, 7132.14, "Control and
Accountability of Labeling Associated with
Tamper-Resistant Packaging of Over-the-Counter Drug
Products"
*J. Compliance Policy Guide, 7132c.06, "Regulatory Action
Regarding Approved New Drugs and Antibiotic Drug Products
Subjected to Additional Processing or other Manipulations"*
*K. Draft Guideline on Repackaging of Solid Oral Dosage Form
Drug Products, October 1992*
ATTACHMENTS
Attachment A - Labeling Requirements For Solid Oral Dosage Forms In
Unit Dosage Containers
Attachment B - Inspectional Guidance on Label Controls
TRANMITTAL NO 02-01 (12/27/93) PART VI PAGE 1 of 2
FORM FDA 2438g (10/91)
第 20 页
PROGRAM 7356.002B
CONTACTS
A. ORA/Office of Operations (OO)
1. Office of Medical Products and Tobacco Operations (OMPTO):
ORAHQDrugInspectionPOC@fda.hhs.gov
2. Office of Regulatory Science
Telephone: (301)796-6600
B. Center for Drug Evaluation and Research
CGMP or any Quality-Related Policy Questions
For CGMP or any quality-related policy question, technical or
scientific questions or
information needs, including questions about this
program, please send an email to the following address
and it will be handled as a top priority:
CDER-OPQ-Inquiries@fda.hhs.gov
Enforcement-Related Guidance or Policy
For enforcement-related guidance or policy, including
evidence need and sufficiency, citations, and case
evaluation/recommendation advice, please send an email to
the following address and it will be handled as a top
priority:
CDER OMQ Compliance Policy: CDEROMQCompliance@fda.hhs.gov
Labeling Requirements and Policies
Office of Unapproved Drugs and Labeling Compliance, see
intranet home page for contacts
[CDER | Office of Compliance | Office of Unapproved Drugs and
Labeling Compliance]
Registration and Drug Listing Requirements
CDER Office of Compliance, see “CDER: Who’s the Lead”
intranet page for contacts
[CDER | Office of Communications | CDER: Who’s the Lead]
TRANMITTAL NO 02-01 (12/27/93) PART VI PAGE 2 of 2
FORM FDA 2438g (10/91)
第 21 页
PROGRAM 7356.002B
PART VII - CENTER RESPONSIBILITIES
Office of Compliance/Office of Unapproved Drugs and Labeling
Compliance (OUDLC)
Assesses the compliance with all labeling requirements of the Federal
Food, Drug, and Cosmetic Act (FD&C Act) and its implementing
regulations for repackaged drugs.
Office of Pharmaceutical Quality (OPQ)
Addresses CGMP, quality-related policy matters, and technical or
scientific issues.
Office of Manufacturing Quality (OMQ)
Identifies the need for enforcement/compliance actions for
repackaging and relabeling operations.
TRANMITTAL NO 02-01 12/27/93) PART VII PAGE 1 of 1
FORM FDA 2438g (10/91)
第 22 页
PROGRAM 7356.002B ATTACHMENT A
LABELING REQUIREMENTS FOR SOLID ORAL DOSAGE
FORMS IN UNIT DOSE CONTAINERS
UNIT DOSE LABELING
A. Prescription Drugs (Solid Oral Dosage Forms, e.g.
Capsules, Tablets)
The label of the actual unit dose container must bear all of the
following information (except item 12 which is not mandatory).
However, where the unit dose container is too small to accommodate
a label with sufficient space to bear all the information, items 10
and 11 may be omitted from the label. If omitted, they must appear,
in addition to all other mandatory items, on the outer enclosing
package from which the unit dose container is to be dispensed. If
there is insufficient space to do so, then the information must be
on a leaflet enclosed with the package.
Note: A firm may not claim an exemption on the basis that the label
is too small to accommodate all mandatory information if all
available space is not utilized or the label size can readily be
made larger, or if the type size on the label can readily be made
smaller without affecting the legibility of the information.
1. The established name of the drug, if it contains a
single active ingredient.
2. The quantity of the active ingredient, and the quantity or
proportion of any ingredient named under Section 502(3) whether
active or not.
3. The expiration date.
4. The lot or control number.
5. The name and place of business of the manufacturer, packer, or
distributor as provided for in 21 CFR 201.1.
6. For official drug products, any pertinent statement
required by the compendia (e.g., refrigerate).
7. If more than one dosage unit is within the unit dose container,
the number of dosage units per container should be specified
(e.g., two capsules rifampin; each capsule contains
300 mg.).
TRANMITTAL NO 02-01 (12/27/93) PAGE 1 of 4
FORM FDA 2438g (2/95)
第 23 页
PROGRAM 7356.002B ATTACHMENT A
8. Special characteristics of the dosage form (e.g., sustained
release, enteric coated sublingual, chewable, need for special
storage conditions).
9. The statement - "Warning: May be habit forming" where
applicable, the controlled drug substances symbol required
by DEA, and the name and proportion of any substance as
required by Section 502(d).
10. If a combination drug, the established name and quantity of
each active ingredient, and the quantity or proportion of
any ingredient named under Section 502(e) whether active or
not.
11. The prescription legend.
12. The National Drug Code designation is recommended, although
this is not mandatory.
In addition to all of the above (except item 12), the following
information must appear on the outer package from which the unit
dose container is dispensed:
1. The number of unit dose containers in the package. If more
than one dosage unit is within each unit dose container,
this should also be stated (e.g., 11100 packets; each packet
contains two tablets," or 11100 packets of two tablets
each").
2. Full disclosure information, as detailed in 21 CFR 201.100.
Where unit dose repackaging is performed by a single
facility for a closed membership or group (e.g. "shared
services") a current package insert bearing adequate
directions for use, located on the premises of each member
to whom the repackaged goods are shipped is sufficient to
satisfy this requirement. The absence of such a current
package insert on the premises of a member to which a drug
is shipped will cause that drug to be misbranded.
B. Non-Prescription Drugs (Solid Oral Dosage Forms, e.g.
Capsules, Tablets)
The label of the actual unit dose container must bear all of the
following information (except item 10 which is not mandatory).
However, where the unit does container is too small to
TRANMITTAL NO 02-01 (12/27/93) PAGE 2 of 4
FORM FDA 2438g (2/95)
第 24 页
PROGRAM 7356.002B ATTACHMENT A
accommodate a label with sufficient space to bear all the
information, item 9 may be omitted from the label. If omitted, this
information must appear, in addition to all other mandatory items, on
the outer enclosing package from which the unit dose is to be
dispensed. If there is insufficient space to do so, the information
must be on a leaf let enclosed within the outer package.
Note: A firm may not claim an exemption on the basis that the label is
too small to accommodate all mandatory information if all available
space is not utilized or the label size can readily be made larger, or
if the type size on the label can readily be made smaller without
affecting the legibility of the information.
1. The- established name of the drug if it contains a single active
ingredient; and the quantity or proportion of any ingredient as
required by Section 502 (e) , and when required, pursuant to
Section 502 (g) by a monograph of an article recognized in an
official compendium, (e.g., Aspirin Tablets).
2. The expiration date.
3. The lot or control number
4. The name and place of business of the manufacturer, packer, or
distributor as provided for in 21 CFR 201.1.
5. For official drug products, any pertinent statement required by
the compendia (e.g., refrigerate).
6. If more than one dosage unit is within the unit dose container,
the number of dosage units per container should be specified
(e.g., two tablets A.S.A.; Each tablet contains 325 mg.).
7. Special characteristics of the dosage form (e.g., sustained
release, enteric coated, chewable, etc.).
8. The statement - "Warning: May be habit forming" where
applicable, and the controlled drug substances symbol required by
DEA, and the name and proportion of any substance as required by
Section 502(d).
TRANMITTAL NO 02-01 (12/27/93) PAGE 3 of 4
FORM FDA 2438g (2/95)
第 25 页
PROGRAM 7356.002B ATTACHMENT A
9. If a combination drug, the established name of each active
ingredient, and the quantities of those ingredients (whether
active or not) specifically named in Section 502(e).
10. The National Drug Code designation is recommended, although
this is not mandatory.
In addition to all of the above (except item 10), the following
information must appear on the outer package from which the unit
dose container is to be dispensed:
1. The number of unit dose containers in the package. If more
than one dosage unit is within each unit dose container this
should also be stated (e.g. 11100 packets; each packet contains
two tablets" or 11100 packets of two tablets each") .
2. The enclosing package or the leaf let enclosed within the
package must bear adequate directions for use as provided for
in 21 CFR 201.5 and should include:
a. Statement of all conditions, purposes, or uses for which
the drug product is intended. ,
b. Quantity of dose, including usual quantities for each of
the uses for which it is intended and usual quantities for
persons of different ages and conditions.
c. Frequency of administration.
d. Duration of administration.
Where unit dose repackaging is performed by a single facility for a
closed membership or group (e.g., shared services) a current package
insert, bearing adequate directions for use, located on the premises
of each member to whom the repackaged goods are shipped is regarded as
satisfying this requirement. The absence of such a current package
insert on the premises of a member to which a drug product is shipped
will cause that drug product to be misbranded.
TRANMITTAL NO 02-01 (12/27/93) PAGE 4 of 4
FORM FDA 2438g (2/95)
第 26 页
.
PROGRAM 7356.002B ATTACHMENT B
INSPECTIONAL GUIDANCE ON LABEL CONTROLS
Inspectional Follow-up to Recalls
Follow-up inspections of all incidents such as recalls should not be
limited to a determination that the recall is being adequately
handled, but should also include a thorough inspection of the firm's
basic controls to determine the underlying cause of the problem, where
possible. Inspectional coverage should not be limited to the lot
recalled. During the investigation of a recall, it should be determined
if the problem is a product mix-up or a label mix-up. When reporting
these recalls, it is important to be specific as to the cause and
to avoid the use of the general term "labeling mix-up."
Inspection of New Registrants
Newly registered drug repackagers or manufacturers should have their
labeling controls examined carefully to determine if the firm is in
compliance with CGMPs. Special attention should be given to new
unit-of-use repackagers. Unit-of-use is a method of repackaging a
medication into a single container which contains more than one dosage
unit (as opposed to unit dose), usually a sufficient quantity of
medication for one normal course of therapy. The general level of
competency of employees in these firms should be evaluated as well as
the firm's training program for new employees. New employees should be
trained to be familiar with all parts of CGMPs. Those employees
working in packaging and labeling departments need special training in
21 CFR 211.122 through 211.134.
Labeling Coverage During Routine Inspections
During routine drug GMP inspections, additional emphasis should be
placed on coverage of label controls if the firm uses cut labels or
roll labels that are similar in color, shape, and size for different
products or different potencies of the same product. Routine
inspections sometimes reveal recalls carried out by firms but not
reported to FDA. For drugs which are subject to NDAs or ANDAs firms
are required by 21 CFR 314.81 to report labeling problems in a “field
alert" to the district office. During routine inspections and follow-
up investigations a determination as to whether the firm is in
compliance with this requirement should be made.
TRANMITTAL NO 02-01 (12/27/93) PAGE 1 of 3
FORM FDA 2438g (2/95)
第 27 页
.
PROGRAM 7356.002B ATTACHMENT B
The use of labels which are similar in size, shape and color for
different products has been a factor in recalls. Cut labels were
involved in 76 percent of recalls in recent years. The use of gang
printing of cut labels should be minimized as required by current
regulations. The use of cut labels which are similar in appearance
and do not have some type of 100 percent electronic verification
system for the finished product have a serious potential for mix-ups
and should be considered inadequate control over the labeling
operation.
Roll labels are known to have less potential for labeling problems.
However, a complete evaluation of the firm's controls of the roll
labeling operation is necessary as problems still arise due to
splicing, failure to adequately review, etc. Again, use of similar
labels without a 100 percent verification system should be avoided.
*(NOTE: New labeling requirements under 21 CFR 211.122(f) and (g),
211.125 (c) and 211.130, published 8/3/93).*
If the firm uses outside contractors to print labeling, it is
important that they have detailed information as to how the printer
controls the printing process. An audit of the printer should be
performed by the firm on a regular basis, and the drug firm must
adequately examine the labeling upon receipt from the printer.
Sampling and inspection should be statistically based; examining
one label per box or roll is not considered adequate. The same
would apply to inspection of finished product for correct labeling.
Use of Multiple Private Labels
Special inspectional emphasis should be placed on firms which
package products under a number of private labels since this type
of firm was involved in the majority of the mislabeling recalls,
including both label and product mix-ups. Controls over storage of
unlabeled stock should be evaluated to determine if they are
adequate to prevent mix-ups. Label controls should be evaluated to
determine if they are adequate to prevent labeling errors.
Unless each unlabeled individual finished product container is
identified as to the product and potency that it contains, or the
unlabeled finished product containers are stored in closed/sealed
cases, or other bulk cartons identified with a solidly affixed
label, this should be considered a significant deviation from GMPs.
TRANMITTAL NO 02-01 (12/27/93) PAGE 2 of 3
FORM FDA 2438g (2/95)
第 28 页
.
PROGRAM 7356.002B ATTACHMENT B
Firms with Multiple Mislabeling Recalls.
Special emphasis should also be placed on any firms which have had
multiple mislabeling recalls in the past few years because a
correlation has been shown between previous recalls and the
probability of additional recalls.
TRANMITTAL NO 02-01 (12/27/93) PAGE 3 of 3
FORM FDA 2438g (2/95)
来源:FDA 官方药品与生物制品信息 · fda.gov